Drug
Valopicitabine clinical trials
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2004
How studies write it
Studies that test it under each name
Name
Studies by the year they started
3 studies that test it; most in 2005 (2)
| Year | Studies |
|---|---|
| 2004 | 1 |
| 2005 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 1
- Phase 2
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 3 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses valopicitabine is read from its arms, and is right about nine times in ten.
Testing it · 3
- Valopicitabine When Administered Alone and in Combination With Interferon to Treatment-Naive Patients With Hepatitis CCompletedPhase 1/2Merck Sharp & Dohme LLCNCT00120835Written as valopicitabine
- Valopicitabine Alone and Together With Pegylated Interferon in Patients With Chronic Hepatitis C Who Have Failed to Respond to Standard TherapyCompletedPhase 2Merck Sharp & Dohme LLCNCT00120861Written as valopicitabine
- A Study to Evaluate the Combination of Pegylated Interferon Alfa Plus Valopicitabine in Patients With Hepatitis CCompletedPhase 2Merck Sharp & Dohme LLCNCT00118768Written as valopicitabine
Codes
What other systems call valopicitabine · ClinicalTrials.gg INT004844
- MeSH (NLM) C506207valopicitabineOne source NLM
- UNII (FDA) I2T0B5G94MVALOPICITABINEConfirmed FDA, NLM, Wikidata
- Wikidata Q27280296valopicitabineConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C66649ValopicitabineOne source FDA
- DrugBank DB13920One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C506207 | valopicitabine | One source NLM |
| UNII (FDA) | I2T0B5G94M | VALOPICITABINE | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27280296 | valopicitabine | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C66649 | Valopicitabine | One source FDA |
| DrugBank | DB13920 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.